- Home
- PRHI vs IMNN Comparison
PRHI vs IMNN Comparison
Compare PRHI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRHI | IMNN |
|---|---|---|
| Founded | 2009 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 12.9M |
| IPO Year | N/A | 1985 |
Fundamental Metrics
Financial Performance| Metric | PRHI | IMNN |
|---|---|---|
| Price | $0.70 | $3.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 93.5K | 75.2K |
| Earning Date | 11-12-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,664,000.00 | N/A |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $2.99 |
| 52 Week High | $2.83 | $41.22 |
Technical Indicators
Market Signals| Indicator | PRHI | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.65 |
| Support Level | N/A | $2.99 |
| Resistance Level | N/A | $4.20 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 77.28 |
Price Performance
Historical ComparisonAbout PRHI Presurance Holdings Inc.
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).